AstraZeneca Stock Rating Reaffirmed by Nordea Equity Research (AZN)
AstraZeneca (LON:AZN)‘s stock had its “buy” rating restated by analysts at Nordea Equity Research in a research report issued to clients and investors on Tuesday, AnalystRatingsNetwork reports. They currently have a GBX 4,218.14 ($69.18) price target on the stock. Nordea Equity Research’s price objective indicates a potential upside of 18.40% from the stock’s previous close.
AstraZeneca (LON:AZN) traded down 1.00% on Tuesday, hitting GBX 3562.50. 2,948,814 shares of the company’s stock traded hands. AstraZeneca has a one year low of GBX 442.867 and a one year high of GBX 3669.50. The stock’s 50-day moving average is GBX 3512.17 and its 200-day moving average is GBX 3297.. The company’s market cap is £44.638 billion.
A number of other analysts have also recently weighed in on AZN. Analysts at JPMorgan Chase & Co. raised their price target on shares of AstraZeneca from GBX 3,200 ($52.48) to GBX 3,700 ($60.69) in a research note to investors on Monday. They now have a “neutral” rating on the stock. Finally, analysts at Jefferies Group reiterated an “underperform” rating on shares of AstraZeneca in a research note to investors on Friday, December 20th. They now have a GBX 2,800 ($45.92) price target on the stock. Thirteen analysts have rated the stock with a sell rating, fifteen have issued a hold rating and five have assigned a buy rating to the company’s stock. AstraZeneca presently has a consensus rating of “Hold” and a consensus price target of GBX 3,117.20 ($51.13).
AstraZeneca PLC (LON:AZN) is a global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.